The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

Julio Montaner(University of British Columbia), Robert S. Hogg(AIDS Vancouver), Evan Wood(Providence Health Care), Thomas Kerr(Providence Health Care), Mark Tyndall(AIDS Vancouver), Adrian R. Levy(University of British Columbia), P. Richard Harrigan(University of British Columbia)

The Lancet

August 1, 2006

10.1016/s0140-6736(06)69162-9

Cited by 553

Abstract

Related Papers

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

Françoise Barré‐Sinoussi, Jean‐Claude Chermann, FA Rey et al.|Science|1983|6.9k

Treatment of latent tuberculosis infection in HIV infected persons

Christopher Akolo, Ifedayo Adetifa, Sasha Shepperd et al.|Cochrane Database of Systematic Reviews|2010|718

The mortality and pathology of HIV infection in a West African city

Sebastian Lucas, A. Hounnou, Christopher S. Peacock et al.|AIDS|1993|566

Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera

R Ashley, Julie Militoni, F Lee et al.|Journal of Clinical Microbiology|1988|540

HIV in the United States at the turn of the century: an epidemic in transition

J M Karon, Patricia L. Fleming, Richard W. Steketee et al.|American Journal of Public Health|2001|477